VANGUARD GROUP INC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.

Quarter-by-quarter ownership
VANGUARD GROUP INC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$500,673,801
+5.7%
13,106,644
-0.2%
0.01%
+9.1%
Q2 2023$473,825,079
-8.2%
13,136,265
-2.8%
0.01%
-15.4%
Q1 2023$516,315,013
-31.8%
13,519,639
+1.6%
0.01%
-38.1%
Q4 2022$756,988,895
+43.6%
13,303,847
-0.2%
0.02%
+31.2%
Q3 2022$527,273,000
-9.9%
13,335,155
+0.3%
0.02%0.0%
Q2 2022$585,061,000
+10.7%
13,296,813
+0.4%
0.02%
+33.3%
Q1 2022$528,407,000
-2.6%
13,249,920
-1.8%
0.01%0.0%
Q4 2021$542,670,000
-2.1%
13,495,913
-1.0%
0.01%
-14.3%
Q3 2021$554,296,000
-10.5%
13,625,741
-0.1%
0.01%
-6.7%
Q2 2021$619,315,000
+12.0%
13,638,304
+2.9%
0.02%0.0%
Q1 2021$552,721,000
-1.6%
13,257,866
+0.8%
0.02%
-6.2%
Q4 2020$561,625,000
+67.9%
13,149,703
+3.3%
0.02%
+45.5%
Q3 2020$334,477,000
-4.4%
12,727,416
-2.5%
0.01%
-8.3%
Q2 2020$349,806,000
+39.9%
13,047,599
-6.1%
0.01%
+9.1%
Q1 2020$250,029,000
+0.7%
13,898,214
-0.7%
0.01%
+37.5%
Q4 2019$248,277,000
+12.5%
14,003,155
-1.6%
0.01%0.0%
Q3 2019$220,678,000
-3.4%
14,228,129
+7.0%
0.01%
-11.1%
Q2 2019$228,442,000
+5.0%
13,296,940
-1.6%
0.01%0.0%
Q1 2019$217,644,000
+10.4%
13,518,190
+0.3%
0.01%0.0%
Q4 2018$197,093,000
-18.5%
13,471,918
+1.2%
0.01%0.0%
Q3 2018$241,977,000
+13.0%
13,317,364
+4.9%
0.01%0.0%
Q2 2018$214,161,000
-9.1%
12,694,846
+5.6%
0.01%
-10.0%
Q1 2018$235,479,000
+3.8%
12,020,363
+7.4%
0.01%0.0%
Q4 2017$226,844,000
+30.7%
11,196,595
+12.1%
0.01%
+25.0%
Q3 2017$173,550,000
+41.1%
9,991,405
+4.1%
0.01%
+33.3%
Q2 2017$123,010,000
+8.3%
9,595,212
+9.5%
0.01%0.0%
Q1 2017$113,576,000
+36.0%
8,763,558
+3.7%
0.01%
+20.0%
Q4 2016$83,509,000
-15.7%
8,452,343
+3.1%
0.01%
-16.7%
Q3 2016$99,047,000
+50.9%
8,199,259
+7.8%
0.01%
+50.0%
Q2 2016$65,658,000
-8.0%
7,608,228
+0.9%
0.00%
-20.0%
Q1 2016$71,374,000
-44.6%
7,536,888
+1.3%
0.01%
-44.4%
Q4 2015$128,938,000
-72.1%
7,440,205
-67.4%
0.01%
-47.1%
Q3 2015$461,610,000
+197.9%
22,809,228
+232.4%
0.02%
+70.0%
Q2 2015$154,961,000
+64.5%
6,862,761
+4.0%
0.01%
+66.7%
Q1 2015$94,192,000
+55.3%
6,596,056
+5.0%
0.01%
+50.0%
Q4 2014$60,647,000
+6.4%
6,284,638
+0.4%
0.00%0.0%
Q3 2014$56,974,000
-6.3%
6,260,802
+1.7%
0.00%
-20.0%
Q2 2014$60,816,000
-22.2%
6,155,526
+0.1%
0.01%
-28.6%
Q1 2014$78,132,000
-1.2%
6,152,087
+16.6%
0.01%0.0%
Q4 2013$79,072,000
+40.2%
5,275,026
+3.3%
0.01%
+16.7%
Q3 2013$56,389,000
+44.0%
5,107,658
+3.6%
0.01%
+50.0%
Q2 2013$39,148,0004,930,4820.00%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Third Security, LLC 19,829,337$266,308,00010.60%
BB BIOTECH AG 6,929,832$93,068,0002.95%
SECTORAL ASSET MANAGEMENT INC 2,671,051$35,872,0001.64%
Sterling Global Strategies LLC 22,000$295,0001.63%
Lombard Odier Asset Management (USA) Corp 1,061,547$14,257,0001.24%
PYRRHO CAPITAL MANAGEMENT, LP 90,000$1,209,0001.04%
IRIDIAN ASSET MANAGEMENT LLC/CT 8,184,003$109,911,0000.93%
Bellevue Asset Management AG 246,000$3,304,0000.54%
Convergence Investment Partners, LLC 251,748$3,381,0000.39%
Rhenman & Partners Asset Management AB 172,000$2,310,0000.37%
View complete list of HALOZYME THERAPEUTICS INC shareholders